DK1011648T4 - Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer - Google Patents
Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancerInfo
- Publication number
- DK1011648T4 DK1011648T4 DK98942057T DK98942057T DK1011648T4 DK 1011648 T4 DK1011648 T4 DK 1011648T4 DK 98942057 T DK98942057 T DK 98942057T DK 98942057 T DK98942057 T DK 98942057T DK 1011648 T4 DK1011648 T4 DK 1011648T4
- Authority
- DK
- Denmark
- Prior art keywords
- tyrosine kinase
- kinase inhibitor
- prostate cancer
- combination
- chemical castration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5589197P | 1997-08-15 | 1997-08-15 | |
PCT/US1998/016849 WO1999008668A2 (en) | 1997-08-15 | 1998-08-13 | Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1011648T3 DK1011648T3 (da) | 2001-12-27 |
DK1011648T4 true DK1011648T4 (da) | 2005-10-24 |
Family
ID=22000842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK98942057T DK1011648T4 (da) | 1997-08-15 | 1998-08-13 | Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer |
Country Status (23)
Country | Link |
---|---|
US (1) | US5985877A (da) |
EP (1) | EP1011648B2 (da) |
JP (1) | JP2001515032A (da) |
KR (1) | KR100612161B1 (da) |
CN (1) | CN1147317C (da) |
AT (1) | ATE208210T1 (da) |
AU (1) | AU737092B2 (da) |
BR (1) | BR9812122A (da) |
CA (1) | CA2299471C (da) |
CZ (1) | CZ297198B6 (da) |
DE (1) | DE69802422T3 (da) |
DK (1) | DK1011648T4 (da) |
EA (1) | EA002525B1 (da) |
ES (1) | ES2163293T5 (da) |
HK (1) | HK1028565A1 (da) |
HU (1) | HUP0003194A3 (da) |
NO (1) | NO325526B1 (da) |
NZ (2) | NZ517497A (da) |
PL (1) | PL193375B1 (da) |
PT (1) | PT1011648E (da) |
TR (1) | TR200000415T2 (da) |
UA (1) | UA61970C2 (da) |
WO (1) | WO1999008668A2 (da) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010080007A (ko) * | 1998-10-08 | 2001-08-22 | 다케다 야쿠힌 고교 가부시키가이샤 | 호르몬 의존성 암의 호르몬 비의존성 암으로의 변화 지연제 |
GB0007371D0 (en) * | 2000-03-28 | 2000-05-17 | Astrazeneca Uk Ltd | Chemical compounds |
GB0008368D0 (en) * | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
US20020169154A1 (en) * | 2001-04-04 | 2002-11-14 | Cephalon, Inc. | Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents |
JP2004528368A (ja) * | 2001-05-08 | 2004-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体と抗ホルモン剤を用いた組合せ療法 |
SE0101697D0 (sv) * | 2001-05-14 | 2001-05-14 | Astrazeneca Ab | Pharmaceutical combination |
IL144583A0 (en) | 2001-07-26 | 2002-05-23 | Peptor Ltd | Chimeric protein kinase inhibitors |
ATE498408T1 (de) * | 2001-08-10 | 2011-03-15 | Takeda Pharmaceutical | Gnrh-agonistische kombinationsmittel |
ES2388170T3 (es) * | 2001-08-24 | 2012-10-09 | Uvic Industry Partnerships Inc. | Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
EP2316487B1 (en) | 2003-04-11 | 2014-06-11 | MedImmune, LLC | Recombinant IL-9 antibodies & uses thereof |
US20040224000A1 (en) * | 2003-05-05 | 2004-11-11 | Romano Deghenghi | Implants for non-radioactive brachytherapy of hormonal-insensitive cancers |
IL156429A0 (en) * | 2003-06-12 | 2004-01-04 | Peptor Ltd | Cell permeable conjugates of peptides for inhibition of protein kinases |
EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
WO2006047639A2 (en) | 2004-10-27 | 2006-05-04 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
AU2006227377B2 (en) | 2005-03-18 | 2013-01-31 | Medimmune, Llc | Framework-shuffling of antibodies |
DK1891093T3 (da) | 2005-06-14 | 2011-07-11 | Protox Therapeutics Inc | Fremgangsmåde til behandling eller forebyggelse af benign prostatahyperplasi ved anvendelse af modificerede poredannende proteiner |
EP1893647A2 (en) | 2005-06-23 | 2008-03-05 | MedImmune, Inc. | Antibody formulations having optimized aggregation and fragmentation profiles |
JP5198289B2 (ja) * | 2006-02-03 | 2013-05-15 | イムクローン・リミテッド・ライアビリティ・カンパニー | 前立腺癌の治療用アジュバントとしてのigf−irアンタゴニスト |
US20080021013A1 (en) * | 2006-07-21 | 2008-01-24 | Cephalon, Inc. | JAK inhibitors for treatment of myeloproliferative disorders |
ES2439994T3 (es) | 2006-08-28 | 2014-01-27 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano |
AU2008232902B2 (en) | 2007-03-30 | 2013-10-03 | Medlmmune, Llc | Antibody formulation |
US20090130195A1 (en) * | 2007-10-17 | 2009-05-21 | Mildred Acevedo-Duncan | Prostate carcinogenesis predictor |
AR085091A1 (es) | 2011-01-26 | 2013-09-11 | Kolltan Pharmaceuticals Inc | Anticuerpos anti-kit y sus usos |
EP4063391A1 (en) | 2012-07-25 | 2022-09-28 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
PT3041507T (pt) | 2013-08-26 | 2021-07-26 | Biontech Res And Development Inc | Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
HUE055189T2 (hu) | 2014-06-04 | 2021-11-29 | Biontech Res And Development Inc | Humán monoklonális antitestek a GD2 ganglioziddal ellen |
PL3333191T3 (pl) | 2014-12-11 | 2021-05-04 | Pierre Fabre Médicament | Przeciwciała przeciwko c10orf54 i ich zastosowania |
FI3265123T3 (fi) | 2015-03-03 | 2023-01-31 | Vasta-aineita, käyttöjä & menetelmiä | |
EP3302568B1 (en) | 2015-05-29 | 2023-12-06 | Memorial Sloan Kettering Cancer Center | Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis |
CN108925136B (zh) | 2015-12-02 | 2022-02-01 | 斯特赛恩斯公司 | 特异于糖基化的btla(b和t淋巴细胞衰减因子)的抗体 |
WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
CN110869057A (zh) | 2017-05-25 | 2020-03-06 | 纪念斯隆凯特琳癌症中心 | 用锆-89标记的超小纳米颗粒及其方法 |
US20200131266A1 (en) | 2017-05-31 | 2020-04-30 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
RU2667906C1 (ru) * | 2017-09-11 | 2018-09-25 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Производное класса N-гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов - N-{ 12-(β-D-ксилопиранозил)-5,7-диоксо-индоло[2,3-а]пирроло[3,4-с] карбазол-6-ил} пиридин-2-карбоксамид, обладающее цитотоксической и противоопухолевой активностью |
WO2019073069A1 (en) | 2017-10-13 | 2019-04-18 | Boehringer Ingelheim International Gmbh | HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN) |
CN112740043A (zh) | 2018-07-20 | 2021-04-30 | 皮埃尔法布雷医药公司 | Vista受体 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4659695A (en) * | 1985-02-08 | 1987-04-21 | Fernand Labrie | Method of treatment of prostate cancer |
US4923986A (en) * | 1987-03-09 | 1990-05-08 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance K-252 |
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
US5461146A (en) † | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
KR100201343B1 (ko) * | 1993-05-28 | 1999-06-15 | 바바라 에스 쉴버그 | 인돌로카르바졸 유도체들의 전립선의 병적상태치료에의 용도 |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
SE506019C2 (sv) * | 1994-05-17 | 1997-11-03 | Forskarpatent I Linkoeping Ab | Ljuskälla av konjugerade polymerer med spänningsstyrd färg samt metod för tillverkning av ljuskällan |
US5591855A (en) * | 1994-10-14 | 1997-01-07 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5475110A (en) * | 1994-10-14 | 1995-12-12 | Cephalon, Inc. | Fused Pyrrolocarbazoles |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5594009A (en) * | 1994-10-14 | 1997-01-14 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US5650407A (en) † | 1995-04-05 | 1997-07-22 | Cephalon, Inc. | Selected soluble esters of hydroxyl-containing indolocarbazoles |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5659407A (en) * | 1995-06-06 | 1997-08-19 | Apple Computer, Inc. | Method and system for rendering achromatic image data for image output devices |
US6211215B1 (en) † | 1996-07-19 | 2001-04-03 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
-
1998
- 1998-08-13 DK DK98942057T patent/DK1011648T4/da active
- 1998-08-13 EA EA200000220A patent/EA002525B1/ru not_active IP Right Cessation
- 1998-08-13 BR BR9812122-7A patent/BR9812122A/pt not_active IP Right Cessation
- 1998-08-13 ES ES98942057T patent/ES2163293T5/es not_active Expired - Lifetime
- 1998-08-13 JP JP2000509408A patent/JP2001515032A/ja active Pending
- 1998-08-13 KR KR1020007001481A patent/KR100612161B1/ko not_active IP Right Cessation
- 1998-08-13 NZ NZ517497A patent/NZ517497A/en unknown
- 1998-08-13 TR TR2000/00415T patent/TR200000415T2/xx unknown
- 1998-08-13 AT AT98942057T patent/ATE208210T1/de not_active IP Right Cessation
- 1998-08-13 US US09/133,567 patent/US5985877A/en not_active Expired - Fee Related
- 1998-08-13 WO PCT/US1998/016849 patent/WO1999008668A2/en active IP Right Grant
- 1998-08-13 EP EP98942057A patent/EP1011648B2/en not_active Expired - Lifetime
- 1998-08-13 CN CNB988081741A patent/CN1147317C/zh not_active Expired - Fee Related
- 1998-08-13 NZ NZ502646A patent/NZ502646A/en unknown
- 1998-08-13 CA CA002299471A patent/CA2299471C/en not_active Expired - Fee Related
- 1998-08-13 AU AU90192/98A patent/AU737092B2/en not_active Ceased
- 1998-08-13 UA UA2000031438A patent/UA61970C2/uk unknown
- 1998-08-13 PT PT98942057T patent/PT1011648E/pt unknown
- 1998-08-13 PL PL98338885A patent/PL193375B1/pl not_active IP Right Cessation
- 1998-08-13 CZ CZ20000469A patent/CZ297198B6/cs not_active IP Right Cessation
- 1998-08-13 DE DE69802422T patent/DE69802422T3/de not_active Expired - Lifetime
- 1998-08-13 HU HU0003194A patent/HUP0003194A3/hu unknown
-
2000
- 2000-02-14 NO NO20000732A patent/NO325526B1/no not_active IP Right Cessation
- 2000-12-13 HK HK00108007A patent/HK1028565A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1011648T4 (da) | Kombination af tyrosinkinase-inhibitor og kemisk kastration til behandling af prostatacancer | |
ATE368466T1 (de) | Androgensyntheseinhibitoren | |
DK0986382T3 (da) | RAF-kinasehæmmere | |
DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
MY121548A (en) | Compounds and methods for the treatment of cancer | |
ID26620A (id) | Penghambatan kinase raf yang menggunakan urea-urea heterosiklik yang disubstitusi | |
DK1039912T3 (da) | Angiostatiske midler og præparater til behandling af GLC1A-glaukom | |
HUP0000261A2 (hu) | Módszer prosztatatúltengés és prosztatarák kezelésére | |
DE60011755D1 (de) | Calciumkanalblocker als antikrebsmittel | |
NO20003848L (no) | FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien | |
RS92304A (en) | Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention | |
IL129705A0 (en) | Use of selected benzotriazole derivatives for protecting human and animal skin and hair from the harmful effects of uv radiation | |
NO984631D0 (no) | <alfa>1-Adrenerge reseptor-antagonister | |
CY1111289T1 (el) | Συνθεσεις αναστολεων ογκου που περιεχουν νιτροακριδινη | |
ATE208202T1 (de) | Verwendung von dimeticon zur behandlung der konstipation | |
NO975838L (no) | Melatoninagonister for behandling av godartet prostatisk hyperplasi | |
MX9710075A (es) | Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna. |